CBD Stock Overview
Cannabis Poland S.A. engages in the retail and wholesale of products based on hemp containing cannabidiol (CBD) in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cannabis Poland S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.57 |
| 52 Week High | zł1.04 |
| 52 Week Low | zł0.28 |
| Beta | 0.78 |
| 1 Month Change | 7.29% |
| 3 Month Change | 78.26% |
| 1 Year Change | 52.46% |
| 3 Year Change | -79.35% |
| 5 Year Change | -26.03% |
| Change since IPO | -47.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| CBD | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | -0.9% | -4.1% | -3.1% |
| 1Y | 52.5% | -5.2% | 24.0% |
Return vs Industry: CBD exceeded the Polish Pharmaceuticals industry which returned -4.5% over the past year.
Return vs Market: CBD exceeded the Polish Market which returned 25.9% over the past year.
Price Volatility
| CBD volatility | |
|---|---|
| CBD Average Weekly Movement | 24.4% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 9.6% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: CBD's share price has been volatile over the past 3 months.
Volatility Over Time: CBD's weekly volatility has increased from 15% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2 | Michal Szary | www.cp-sa.pl |
Cannabis Poland S.A. engages in the retail and wholesale of products based on hemp containing cannabidiol (CBD) in Poland. The company sells CBD oils and herbs, inhalers, and vaporizers, as well as cosmetics. It sells its products through HempWish.pl and Vapem.eu online stores.
Cannabis Poland S.A. Fundamentals Summary
| CBD fundamental statistics | |
|---|---|
| Market cap | zł28.24m |
| Earnings (TTM) | -zł1.23m |
| Revenue (TTM) | zł65.55k |
430.8x
P/S Ratio-23.0x
P/E RatioIs CBD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBD income statement (TTM) | |
|---|---|
| Revenue | zł65.55k |
| Cost of Revenue | zł95.35k |
| Gross Profit | -zł29.80k |
| Other Expenses | zł1.20m |
| Earnings | -zł1.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -0.025 |
| Gross Margin | -45.46% |
| Net Profit Margin | -1,869.25% |
| Debt/Equity Ratio | 8.1% |
How did CBD perform over the long term?
See historical performance and comparison